Bipolar depression - Articles - Page 2

RESEARCH UPDATE

Pediatric Bipolar Depression: How Do We Rate a New Meta-Analysis?

October 1, 2022

Dr. Algon, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Clinicians use olanzapine, mirtazapine, and other appetite-inducing medications off label to treat ARFID, but with little research to support their use. This study unpacks the potential role of medications in treating comorbid symptoms associated with ARFID.

EXPERT Q&A

Personality Changes Later in Life: Diagnostic and Treatment Considerations

July 1, 2022

Rajesh R. Tampi, MD, MS, DFAPA.

Rajesh R. Tampi, MD

Professor and chairman, Department of Psychiatry, Bhatia Family Endowed Chair in Psychiatry, Creighton University School of Medicine. Catholic Health Initiatives (CHI) Behavioral Health Services, Omaha, NE.

Dr. Tampi, expert for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Dr. Rajesh R. Tampi describes the course of personality disorders as patients age and provides documentation tips for clinicians who suspect personality disorders.

12 New Findings on Quetiapine

June 6, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

12 clinically relevant findings from the past 3 years on quetiapine (Seroquel), including new side effects, dosing strategies, withdrawal phenomena, and new uses in bipolar with OCD.

Quetiapine Reconsidered

June 1, 2022

Paul Riordan, MD.

Paul Riordan, MD. Assistant Consulting Professor of Psychiatry, Duke University. Dr. Riordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

It is the best of drugs; it is the worst of drugs. Quetiapine (Seroquel) has a few benefits that are unmatched by other medications, and here we explore where it fits in depression, bipolar, schizophrenia, as well as off-label uses like anxiety and sleep.